Keyphrases
Migraine
64%
Migraine without Aura (MWoA)
49%
Headache
44%
Calcitonin Gene-related Peptide
34%
Migraine Attack
32%
Healthy Volunteers
20%
Post-traumatic Headache
20%
MRI Study
17%
Placebo
16%
Mild Traumatic Brain Injury (mTBI)
15%
Erenumab
14%
Migraine Patients
14%
Functional Magnetic Resonance Imaging
14%
Pituitary Adenylate Cyclase-activating polypeptide-38
14%
Meta-analysis
13%
Migraine Prevention
13%
Migraine-like
12%
Chronic Migraine
11%
Monthly Migraine Days
10%
European Headache Federation
9%
Pituitary Adenylate Cyclase-activating Polypeptide (PACAP)
9%
Randomized Clinical Trial
9%
3T MRI
8%
Vasoactive Intestinal Polypeptide
8%
Single Center
8%
Fremanezumab
7%
Episodic Migraine
7%
Clinical Features
7%
Middle Meningeal Artery
7%
Healthy Controls
7%
Systematic Meta-analysis
7%
Migraine Pathophysiology
7%
Magnetic Resonance Angiography
7%
Middle Cerebral Artery
7%
Migraine Treatment
6%
Headache Disorders
6%
Monoclonal Antibody
6%
Preventive Treatment
6%
Sildenafil
6%
Cortical Thickness
6%
Cromakalim
5%
MR Angiography
5%
Adverse Events
5%
Brain Connectivity
5%
Magnetic Resonance Imaging Study
5%
Intradural
5%
Oral Drugs
5%
Migraine Headache
5%
Visual Stimulation
5%
Extracranial
5%
Medicine and Dentistry
Migraine
77%
Headache
45%
Calcitonin Gene Related Peptide
19%
Systematic Review
16%
Migraine without Aura
13%
Auras
13%
Magnetic Resonance Angiography
13%
Posttraumatic Headache
12%
Migraine with Aura
12%
Artery
12%
Magnetic Resonance Imaging
12%
Migraine Aura
12%
Volunteer
11%
Meta-Analysis
11%
Traumatic Brain Injury
9%
Hypophysis Adenylate Cyclase Activating Polypeptide
9%
Placebo
9%
Clinical Feature
9%
Infusion
9%
Erenumab
9%
Functional Magnetic Resonance Imaging
9%
Cohort Effect
7%
Symptom
7%
Middle Cerebral Artery
6%
Middle Meningeal Artery
6%
Headache and Facial Pain
6%
Transformed Migraine
6%
Fremanezumab
5%
Vasoactive Intestinal Polypeptide
5%
Aura (Symptom)
5%
Neuroscience
Migraine
100%
Headache
49%
Auras
36%
Calcitonin
23%
Hypophysis Adenylate Cyclase Activating Polypeptide
18%
Functional Magnetic Resonance Imaging
17%
Magnetic Resonance Imaging
16%
Placebo
15%
Neurotrauma
13%
Traumatic Brain Injury
13%
Magnetic Resonance Imaging
10%
Adenosine Triphosphate Sensitive Potassium Channel
10%
Magnetic Resonance Angiography
9%
Gray Matter
7%
Middle Meningeal Artery
6%
Vasoactive Intestinal Peptide
6%
Middle Cerebral Artery
6%
Blood Brain Barrier
5%
Meta-Analysis
5%
